Malignant pleural mesothelioma is a rare thoracic solid tumor cancer that has been strongly linked to asbestos exposure.
It causes symptoms, such as chest pain and shortness of breath, that are frustratingly similar to those of more common illnesses. There are approximately 3,000 new cases of mesothelioma annually in the United States.
Last year, the FDA approved a new treatment for MPM called Optune Lua, which is the first treatment approved by the FDA for the disease in more than 15 years. Optune Lua is a wearable and portable cancer treatment that delivers Tumor Treating Fields (TTFields) to the region of the tumor.
TTFields are low-intensity alternating electric fields tuned to specific frequencies that continuously disrupt cancer cell division.
For more information, click here.